Medical Condition

rheumatoid arthritis

Q: How many clinical trials are currently recruiting for rheumatoid arthritis?

ClinicalMetric currently tracks 11 actively recruiting clinical trials for rheumatoid arthritis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

Q: What trial phases are available for rheumatoid arthritis?

rheumatoid arthritis research spans Phase 1 (3 trials), Phase 2 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

Q: How do I find out if I qualify for a rheumatoid arthritis clinical trial?

Eligibility criteria for rheumatoid arthritis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Total Trials

11

Recruiting Now

11

Trial Phases

Phase 4, Phase 1, Phase 2

Rheumatoid arthritis trials now operate in a treat-to-target paradigm where clinical remission (DAS28 < 2.6) is the primary goal, and biologics failure triggers a logical sequence of mechanism switching. The JAK inhibitor class (tofacitinib, baricitinib, upadacitinib) has added an oral option after TNF/IL-6 inhibitor failure, though cardiovascular safety signals have reshaped prescribing guidance.

Active trials evaluate next-generation JAK inhibitors with improved selectivity, IL-17A/F bispecifics, TYK2 inhibitors, CAR-T cell therapy for refractory disease, and precision medicine biomarkers (MBDA score, synovial biopsy) to guide treatment selection. Tapering and de-escalation in sustained remission is a growing research priority.

Frequently Asked Questions — rheumatoid arthritis Clinical Trials

How many clinical trials are currently recruiting for rheumatoid arthritis?

ClinicalMetric currently tracks 11 actively recruiting clinical trials for rheumatoid arthritis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for rheumatoid arthritis?

rheumatoid arthritis research spans Phase 1 (3 trials), Phase 2 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a rheumatoid arthritis clinical trial?

Eligibility criteria for rheumatoid arthritis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 4

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology